Home Resources Webinars

Webinars

See If Your Capsid Is Full of It: Easily Quantify and Characterize Full and Empty AAV

In this GEN webinar, sponsored by Unchained Labs, you will learn about some new tools and strategies to get you answers on empty/full ratio, quantification, aggregation, and the stability of your capsids with teeny-tiny sample volumes.

Advances in AAV Vectors and Gene Therapy

In this timely GEN Keynote webinar, sponsored by Aldevron, renowned AAV pioneer Dr. Guangping Gao (UMass Medical School/editor, Human Gene Therapy) will discuss the principles, history, challenges, and future directions of human gene therapy using AAVs. Dr. Gao will focus on progress in treating rare diseases and detail AAV capsid engineering to modulate target tissue tropism, therapeutic gene expression, and cassette design/optimization. Dr. Gao will also share examples of AAV gene therapy development: from proof-of-concept preclinical studies to first-in-human clinical evaluation.

The Great Convergence: How Biology and Engineering Unite to Reshape our World

In this webinar—the third in the “Women in Science” series co-hosted by GEN and the Rosalind Franklin Society—renowned neuroscientist Dr. Susan Hockfield, who served as president of MIT from 2004–2012, will share her views of the future that she lays out in her recent book, The Age of Living Machines: How Biology Will Build the Next Technology Revolution.

Innovative Technology for Insights into Receptor Tyrosine Kinase Biology

In this GEN webinar, our expert panelists will introduce bioSensAll™, an enhanced bystander bioluminescence resonance energy transfer (ebBRET)-based biosensor technology and its applications to interrogate RTK biology and expand current RTK drug discovery efforts.

Rapid Development of Multitagged Cell Lines for Drug Discovery

In this GEN webinar, sponsored by Tecan, we will discuss the development of the FAST-HDR vector system (patent pending)—a novel set of plasmids to be used in combination with CRISPR for the rapid development of multi-tagged cell lines for drug discovery. These plasmids allow the insertion of protein tags in genes of interest for downstream applications such as high-content imaging or luminescence detection on live cells. We will present examples of the use of these enhanced cellular models for high-throughput screening, target characterization, and live-cell microscopy.

Biomanufacturing Assumes Central Role in Cell and Gene Therapies

In this GEN Keynote webinar, Dr. Peter Marks, director of the Center for Biologics Evaluation and Research (CBER) at the FDA, will share how CBER is providing oversight to organizations during the critical developmental and manufacturing stages for biological products, as well as throughout the product life cycle.

The Secret to Improving the Therapeutic Index of Antibody Drug Conjugates

REGISTER NOW Broadcast Date: February 5, 2019 Time: 8:00 am PT, 11:00 am ET, 17:00 CET Antibody-drug conjugates (ADCs) were initially developed to provide a selective targeting...

Preventing Dementia through a Virtual Twin Brain

GEN's on demand webinar, sponsored by Dassault Systèmes, discusses the current state of The Living Brain Project and how it is being applied to traumatic brain injury, neuromodulation, neurodegenerative disease progression, and drug delivery through cerebrospinal fluid.

Streamlined Formulation of Enzyme Products

REGISTER NOW Broadcast Date: February 26, 2019 Time: 8:00 am PT, 11:00 am ET, 17:00 CET There are two complementary paths to creating a stable enzyme formulation....

How to Decrease Long Read Sequencing Sample QC Time by 10-Fold

This presentation will show how low concentrated samples, as well as libraries prepared for long read sequencing benefit from QC, performed with the Femto Pulse.

Association Rate Constant: The Unsung Hero of Drug Discovery Kinetics

While the importance of ligand-receptor binding kinetics on drug action is becoming well established, focus to date has been almost entirely on the role of the dissociation constant on drug efficacy and duration of action. The association rate constant, in contrast, has been largely overlooked, with many investigators still considering it diffusion-limited and equivalent across a compound series. This GEN webinar aims to remedy that by turning the spotlight onto the undervalued and oft-ignored association rate constant.

Recent Advances and the Future of Antibody Engineering

In this GEN webinar, we will hear from Danica Stanimirovic MD, PhD, and Danica Stanimirovic MD, PhD, wto leading scientists who will describe their current antibody engineering research projects and the therapeutic potential they hold.

Pancreatic Cancer Therapeutic Target Visualized Using In Situ Hybridization

In this GEN webinar sponsored by Advanced Cell Diagnostics, we will hear about new PDAC research showing that the cytokine leukemia inhibitory factor (LIF) key paracrine factor from activated pancreatic stellate cells acting on cancer cells.

Measuring Multivalent Interactions: Uncovering the Secrets of Virus Binding Strategies

In this GEN webinar, we will learn from Dr. Daniel Lauster, who, when faced with many of the challenges described above, utilized MicroScale Thermophoresis (MST) to measure the interaction between more than 100 novel non-toxic multivalent nanoparticle-conjugates and intact IAV in solution with as little as nanomoles of nanoparticles. Additionally, we will hear from Dr. Matthias Molnar how MST is becoming scientists’ first choice for the characterization of molecular interactions thanks to its flexible throughput, low sample consumption, and measurements in solution or in close to native conditions.

Mind the Yap! Single-Cell Transcriptomes Reveal Drivers of Intestinal Regeneration

In this GEN webinar, we will hear about recent findings implicating the Hippo effector, Yap, as a driver of a novel damaged-induced intestinal stem cell population.

Managing Multiple Biomarker Therapeutic Development

In this roundtable, our panelists will discuss assessing the validity of biomarkers to inform drug development and potential combination therapies. Key considerations include predictive testing of biomarkers, analytical methods, drug-diagnostic co-development and potential reimbursement considerations.

Recently Featured

Scroll Up